- Home
- GAM vs CLDX Comparison
GAM vs CLDX Comparison
Compare GAM & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- CLDX
- Stock Information
- Founded
- GAM 1927
- CLDX N/A
- Country
- GAM United States
- CLDX United States
- Employees
- GAM N/A
- CLDX N/A
- Industry
- GAM Investment Managers
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GAM Finance
- CLDX Health Care
- Exchange
- GAM Nasdaq
- CLDX Nasdaq
- Market Cap
- GAM 1.2B
- CLDX 1.3B
- IPO Year
- GAM N/A
- CLDX 2008
- Fundamental
- Price
- GAM $54.09
- CLDX $19.78
- Analyst Decision
- GAM
- CLDX Buy
- Analyst Count
- GAM 0
- CLDX 9
- Target Price
- GAM N/A
- CLDX $50.00
- AVG Volume (30 Days)
- GAM 20.1K
- CLDX 931.3K
- Earning Date
- GAM 01-01-0001
- CLDX 05-08-2025
- Dividend Yield
- GAM 5.74%
- CLDX N/A
- EPS Growth
- GAM N/A
- CLDX N/A
- EPS
- GAM 11.67
- CLDX N/A
- Revenue
- GAM N/A
- CLDX $7,559,000.00
- Revenue This Year
- GAM N/A
- CLDX N/A
- Revenue Next Year
- GAM N/A
- CLDX N/A
- P/E Ratio
- GAM $3.95
- CLDX N/A
- Revenue Growth
- GAM N/A
- CLDX 24.49
- 52 Week Low
- GAM $37.32
- CLDX $14.40
- 52 Week High
- GAM $46.48
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- GAM 66.44
- CLDX 50.54
- Support Level
- GAM $53.40
- CLDX $18.55
- Resistance Level
- GAM $54.46
- CLDX $20.67
- Average True Range (ATR)
- GAM 0.79
- CLDX 1.21
- MACD
- GAM 0.02
- CLDX -0.08
- Stochastic Oscillator
- GAM 84.71
- CLDX 49.25
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.